What question did this study set out to answer?

This research investigates how leukemic stem cells exploit niche interactions for drug resistance in acute myeloid leukemia.

June 22, 2026Open Access

Leukemic stem cell–niche interaction through CLEC2-podoplanin axis confers drug resistance in acute myeloid leukemia

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial shows that the CLEC2-Pdpn axis drives drug resistance in acute myeloid leukemia, suggesting new treatment strategies.

This research investigates how leukemic stem cells exploit niche interactions for drug resistance in acute myeloid leukemia.
Established an in vivo-selected subline of human AML cell line KG-1a using serial xenografting in NOD/SCID mice.
Evaluated CLEC2 expression in primary AML leukemic stem cells and performed co-culture assays with stromal cells expressing podoplanin.
Assessed chemosensitivity to drugs cytarabine and venetoclax.
rKG-1a showed enhanced engraftment despite slower proliferation in vitro.
CLEC2 was significantly upregulated in AML leukemic stem cells compared to healthy hematopoietic stem cells.
CLEC2high leukemic stem cells exhibited resistance to cytarabine when co-cultured with podoplanin-expressing stroma.

lwata et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark